To evaluate the long-term efficacy and safety of certolizumab pegol ( CZP ) treatment and to assess the efficacy of two CZP maintenance dosing schedules in Japanese rheumatoid arthritis ( RA ) patients who could not receive methotrexate ( MTX ) .